Related content

Hemolytic uremic syndrome: an unusual complication of interferon-β treatment in a MS patient

By Nerrant Elodie   Charif Mahmoud   Ramay Anne-Sophie   Perrochia Hélène   Patrier Laure   Champfleur Nicolas   Renard Dimitri   Labauge Pierre  

Journal of Neurology, Vol. 260, Iss. 7, 2013-07 ,pp. : 1915-1916

Springer Publishing Company

Access to resources Recommend Favorite

Is haematopoietic stem cell transplantation a treatment option for severe MS or not?

By Martin Roland  

Brain, Vol. 130, Iss. 5, 2007-05 ,pp. : 1181-1182

Oxford University Press

Access to resources Recommend Favorite

Cholinesterase inhibitors in Alzheimer's disease: a consensus view on managing treatment failure

By Emre Murat   Farlow Martin   Bullock Roger   Gauthier Serge   Grossberg George   Potkin Steven G  

Primary Care Psychiatry, Vol. 9, Iss. 1, 2004-01 ,pp. : 29-30

Informa Healthcare

Access to resources Recommend Favorite

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

By Polman C.  

Journal of Neurology, Vol. 255, Iss. 4, 2008-04 ,pp. : 480-487

Springer Publishing Company

Access to resources Recommend Favorite

Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study

By Zivadinov Robert   Ramanathan Murali   Ambrus Julian   Hussein Sara   Ramasamy Deepa P   Dwyer Michael G   Bergsland Niels   Minagar Alireza   Weinstock-Guttman Bianca  

Neurological Research, Vol. 34, Iss. 8, 2012-10 ,pp. : 761-769

Maney Publishing

Access to resources Recommend Favorite